Integra LifeSciences Holdings Corporation reported a total revenue of $391.9 million for the three months ended March 31, 2026, marking a 2.4% increase from $382.7 million in the same period of 2025. The company achieved an operating income of $11.5 million, a significant turnaround from an operating loss of $15.5 million in the prior year. The net loss for the quarter was $4.6 million, or $(0.06) per share, compared to a net loss of $25.3 million, or $(0.33) per share, in the previous year. This improvement in financial performance is attributed to reduced operational challenges and enhanced revenue generation across its product lines.

The Specialty Surgery segment generated $283.1 million in revenue, a slight increase of 1% from the previous year, while the Tissue Reconstruction segment saw a more substantial growth of 6.7%, reaching $108.8 million. The growth in the Tissue Reconstruction segment was primarily driven by recovery in product availability and sales, particularly in Integra Skin and DuraSorb, despite facing quality and operational issues with Medihoney products. Gross margin improved to 55.4% from 50.8% year-over-year, reflecting better cost management and increased sales.

In terms of operational developments, Integra LifeSciences has made strategic changes, including the renaming of its reportable segments to better align with its business activities. The company also reported a decrease in total operating expenses, which fell by 2.1% to $205.5 million, driven by reduced selling, general, and administrative costs. The company’s workforce remained stable, with a slight increase in employee headcount, reflecting ongoing investments in its operational capabilities.

The company continues to navigate challenges related to tariffs and macroeconomic conditions, which have impacted its cost structure. In response to recent tariff rulings, Integra recognized a receivable of $18.7 million for previously paid tariffs that are subject to refund. Looking ahead, the company anticipates continued revenue growth driven by product innovation and geographic expansion, particularly in markets such as China and Europe. The operationalization of its new manufacturing facility in Braintree, Massachusetts, is expected to further enhance production capabilities and support future growth initiatives.

About INTEGRA LIFESCIENCES HOLDINGS CORP

Integra LifeSciences is a global medical technology company specializing in surgical, neurosurgical, ENT, and regenerative care products. It offers advanced devices and regenerative solutions for brain, spine, wound, and reconstructive procedures. Serving hospitals, clinics, and surgeons worldwide, the company emphasizes innovation, quality, and expanding care pathways, with a focus on improving patient outcomes through leading-edge technologies and strategic acquisitions.

This description was generated via AI from an annual report. Updated 8 months ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.